When “Normal” Blood Sugar Feels Too Low: New Research May Explain Why

When glucose numbers improve, patients are expected to feel better. Yet some people with type 1 diabetes report the opposite. A glucose level that looks reassuring on a continuous glucose monitor may leave them feeling tired, uncomfortable, or simply “off.” New research suggests that glycemic habituation may help explain this apparent contradiction. The concept could give clinicians a useful framework for understanding why moving toward recommended glucose targets does not always feel better immediately.

Table of Contents

• What glycemic habituation means
• What the new type 1 diabetes research found
• Why personal glucose range matters
• How clinicians can respond
• Conclusion
• Frequently asked questions

What Is Glycemic Habituation in Type 1 Diabetes?

The basic idea behind glycemic habituation is straightforward. When someone spends substantial time at elevated glucose levels, the body may become accustomed to that glucose environment. Consequently, moving toward a healthier range can initially feel unfamiliar or uncomfortable.

This does not necessarily mean the patient is experiencing true hypoglycemia. According to the American Diabetes Association’s 2026 Standards of Care, level 1 hypoglycemia begins below 70 mg/dL. For many nonpregnant adults, the recommended CGM time-in-range window is 70 to 180 mg/dL.

However, the patient’s experience may not line up neatly with those thresholds.

Imagine someone whose glucose has routinely remained well above 180 mg/dL. A reading of 110 or 120 mg/dL may be clinically desirable, yet it represents a major change from what that person’s body usually experiences. Therefore, symptoms during glucose improvement deserve attention rather than immediate dismissal.

This distinction is important because symptoms alone cannot establish true hypoglycemia. At the same time, a glucose reading within the recommended range does not mean a patient’s symptoms are irrelevant.

New Research Examines Personal Versus Guideline Glucose Ranges

A 2026 study published in Diabetes Care provides new insight into this issue. Researchers studied 161 adults with type 1 diabetes using blinded continuous glucose monitoring for 14 days. Participants also completed real-time assessments and mobile cognitive tests six times each day.

Rather than looking only at standard time in range, researchers compared two measures. The first was conventional time in range, defined as 70 to 180 mg/dL. The second was “time in personal range,” or TIPR, defined around each participant’s own mean glucose, plus or minus 50 mg/dL.

That comparison produced an interesting result.

Time in personal range was more consistently associated with better pain, fatigue, activity demands, and perceptual speed than conventional time in range. Meanwhile, guideline-based time in range showed stronger associations with diabetes-specific measures, including diabetes distress and self-care.

Importantly, personal range explained additional differences in several outcomes even after researchers accounted for standard time in range.

These findings do not establish that a person’s habitual glucose range is medically optimal. Instead, they suggest that adaptation to a person’s usual glucose levels may influence how patients feel and function in everyday life.

The research also supports a broader lesson for CGM interpretation. As discussed in Diabetes in Control’s practical guide to using time in range, CGM data can help clinicians look beyond A1C and identify patterns that affect daily management.

Why “Normal” Glucose May Feel Uncomfortable

For clinicians, one of the most important implications is that feeling low and being clinically hypoglycemic are not necessarily the same thing.

Patients accustomed to higher glucose may report symptoms as their readings fall toward recommended targets. Habituation to chronically elevated glucose levels offers one possible explanation, because a person’s usual glucose exposure may influence physiological and perceptual thresholds.

Still, the new findings should not be interpreted as evidence that chronic hyperglycemia is beneficial. Long-term glucose management remains essential for reducing diabetes complications. Likewise, clinicians should not automatically raise glucose targets simply because a patient feels more comfortable at higher values.

Instead, personal glucose range may offer context.

For example, a patient whose glucose has historically averaged 220 mg/dL may have a very different experience at 100 mg/dL than someone who regularly spends most of the day between 80 and 150 mg/dL. The meter displays the same number, but the lived experience may differ.

Clinicians should also distinguish these symptoms from actual hypoglycemia and impaired hypoglycemia awareness. Diabetes in Control has previously reviewed the importance of hypoglycemia awareness in type 1 diabetes. CGM trends, insulin timing, recent activity, meals, and confirmed glucose readings can help clarify what is happening.

Turning Glycemic Adaptation Into Better Clinical Conversations

The practical message is not to replace evidence-based targets with a patient’s habitual glucose range. Rather, clinicians can use both pieces of information to understand the patient more completely.

First, acknowledge the symptoms. Telling a patient that 120 mg/dL is “normal” does little to address the fact that they feel shaky, tired, or uncomfortable. Recognizing the experience can strengthen communication and make glucose management feel more collaborative.

Next, review the CGM pattern instead of focusing on one reading. A rapidly falling glucose level may feel different from a stable glucose level, even when both remain above 70 mg/dL. Clinicians should therefore examine trend arrows, time below range, glucose variability, insulin exposure, and the patient’s usual glucose profile.

Gradual progress may also be appropriate for selected patients. The ADA emphasizes individualized glycemic goals, shared decision-making, hypoglycemia prevention, and consideration of treatment burden. For many nonpregnant adults, an A1C below 7% and time in range above 70% are appropriate goals when they can be achieved safely.

However, personalization should not become therapeutic inertia. The purpose of understanding this adaptation to higher glucose levels is not to normalize persistent hyperglycemia. Instead, it may help clinicians explain temporary discomfort, address concerns, and develop a tolerable path toward safer long-term glucose management.

Ultimately, the new research adds another dimension to patient-centered diabetes care: glucose numbers matter, but so does how patients function and feel while those numbers change.

Conclusion

Habituation to higher glucose levels may help explain a familiar clinical puzzle in type 1 diabetes: why moving into a recommended glucose range can sometimes make a patient feel worse before it feels better.

The latest research suggests that a person’s usual glucose environment can provide meaningful information about fatigue, pain, daily functioning, and other aspects of lived experience. However, personal glucose range should complement rather than replace established CGM targets.

For clinicians, the opportunity is to combine objective glucose data with careful listening. Recognizing symptoms, confirming whether true hypoglycemia is present, reviewing CGM trends, and individualizing the pace of treatment can help patients move toward evidence-based goals without dismissing what they experience along the way.

Frequently Asked Questions

What is glycemic habituation?

It describes how repeated exposure to higher glucose levels may change the way a person physiologically or perceptually experiences lower glucose levels. As a result, glucose within a guideline-recommended range may initially feel uncomfortable.

Can someone feel hypoglycemic when glucose is above 70 mg/dL?

A person may report symptoms associated with falling glucose even when the measured value is above the clinical hypoglycemia threshold. Clinicians should confirm glucose levels and trends rather than relying on symptoms alone.

What is time in personal range?

In the 2026 study, time in personal range was calculated using each participant’s mean glucose plus or minus 50 mg/dL. It was designed as a research measure of the glucose environment most typical for that individual, not as a replacement treatment target.

Does glycemic habituation mean clinicians should accept higher glucose targets?

No. The research does not establish chronic hyperglycemia as desirable or suggest abandoning evidence-based targets. Instead, it may help explain patient symptoms and support individualized, patient-centered approaches to reaching safer glucose levels.

How should clinicians respond when normal glucose feels too low?

Confirm the glucose level, evaluate CGM trends and true hypoglycemia risk, listen to the patient’s symptoms, and review the treatment plan. When appropriate, clinicians can individualize how glycemic goals are approached while continuing to work toward safe, evidence-based targets.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.